FASTER ACCESS TO CANCER MEDICINES MEANS U.S. PATIENTS LIVE LONGER

Timely access to innovative medicines can help protect patients' time, health and lives.



Faster availability of new cancer medicines delivers an extra year of life for nearly 10,000 patients annually.

Additional Years of Life Gained Through Earlier Access to Medicines in the U.S. Compared with EU5

Multiple Myeloma
20 months faster
2,315 more years of life annually

Non-Small Cell Lung Cancer
17 months faster
4,229 more years of life annually

Colorectal Cancer
15 months faster
914 more years of life annually

Metastatic Breast Cancer
22 months faster
482 more years of life annually

Metastatic Prostate Cancer
18 months faster
1,666 more years of life annually

Metastatic Melanoma
13 months faster
81 more years of life annually

Access delays to cancer therapies in Europe vary across countries and cancer types, with some patients waiting **more than 3 years** longer for treatments available in the U.S.

The longest delay identified:
39 months
for metastatic breast cancer treatments in Spain.

MORE TIME with family, friends and loved ones.

MORE TIME for treatment to work.

MORE TIME for the next breakthrough to arrive.

Source: GlobalData oncology microsimulation commissioned by the Partnership to Fight Chronic Disease.
EU5 = France, Germany, Italy, Spain and United Kingdom.

PARTNERSHIP TO FIGHT CHRONIC DISEASE